Ignacio Zabaleta, MD
Psychiatry · Hollywood, FLNPI 1033571633
Payments from drug & device makers
Across 764 payments — averaging $68.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$39K
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Johnson & Johnson$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$931
- Neurocrine Biosciences, Inc.$922
- plus $7K from 28 others
What the payments were for
- Consulting fees$6,23012%
- Speaking & faculty fees$27,94053%
- Travel & lodging$2,4355%
- Food & beverage$15,77730%
- Education$1160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 99 | $39,373 |
| AbbVie(2 entities) | 98 | $1,835 |
| Teva Pharmaceuticals USA, Inc. | 98 | $1,368 |
| Johnson & Johnson | 74 | $1,352 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 41 | $931 |
| Neurocrine Biosciences, Inc. | 32 | $922 |
| Otsuka America Pharmaceutical, Inc. | 45 | $904 |
| Indivior Inc. | 39 | $886 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $688 |
| Almatica Pharma LLC | 33 | $634 |
| Vanda Pharmaceuticals Inc. | 25 | $592 |
| Bausch Health US, LLC | 26 | $513 |
| Axsome Therapeutics, Inc. | 25 | $506 |
| Corium, LLC | 24 | $477 |
| Sunovion Pharmaceuticals Inc. | 14 | $286 |
| Idorsia Pharmaceuticals US Inc | 9 | $195 |
| Orexo US, Inc. | 8 | $149 |
| E.r. Squibb & Sons, L.L.C. | 6 | $145 |
| Lundbeck LLC | 7 | $128 |
| Braeburn Inc. | 6 | $124 |
| Alfasigma USA, Inc. | 5 | $87 |
| Collegium Pharmaceutical, Inc. | 4 | $83 |
| Merck | 3 | $53 |
| Ironshore Pharmaceuticals Inc. | 2 | $37 |
| Neos Therapeutics, LP | 2 | $35 |
| Luye Pharma (USA) Ltd. | 2 | $34 |
| Tempus AI, Inc | 1 | $29 |
| Supernus Pharmaceuticals, Inc. | 1 | $27 |
| Tris Pharma Inc | 1 | $21 |
| Eisai Inc. | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Brainsway USA Inc | 1 | $18 |
| Adlon Therapeutics L.p. | 1 | $17 |
| Noven Therapeutics, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$52,499 in reported general payments places this provider in the 90th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 40 | $62,994 |
| RexultiBrexpiprazole | 25 | $39,422 |
| ClozarilClozapine | 11 | $22,584 |
| TrintellixVortioxetine Hydrobromide | 30 | $17,995 |
| Clozapine OdtClozapine | 12 | $8,479 |
| Lurasidone Hcl | 33 | $8,320 |
| Adderall XrDextroamphetamine/Amphetamine | 17 | $5,863 |
| Aripiprazole | 140 | $5,355 |
| Asenapine Maleate | 18 | $5,324 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,656 |
| Clonazepam | 288 | $3,852 |
| Duloxetine Hcl | 161 | $2,994 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 21 | $2,732 |
| Lamotrigine ErLamotrigine | 15 | $2,457 |
| Bupropion XlBupropion Hcl | 135 | $2,423 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,835 | $62,99440 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $904 | $39,42225 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $688 | $22,65142 claims |
| Almatica Pharma LLCSertraline Hcl | $634 | $1,105168 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Hollywood
- Hernan PabonHollywood$1.2M
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- John JoyceJacksonville$13.6M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
- Patricia JunqueraMiami$10.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.